Clinical Trials Browser

Completed × Observational × Triple Negative Breast Neoplasms × Clear all

NCT03586297 2026-03-27

Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer

Triple Negative Breast Neoplasms

NCT07211451 2025-10-08

Axillary Nodal Burden in HER2+ and TNBC

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06965361 2025-05-16

TIL; PD1; PDL1

Triple Negative Breast Neoplasms

NCT03981705 2024-12-27

Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05111067 2024-08-21

Molecular Subtyping of Triple-negative Breast Cancer and African Ancestry-related Immunogenicity

Triple Negative Breast Neoplasms

NCT06309459 2024-03-13

Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma

Triple Negative Breast Neoplasms

NCT05071677 2023-08-09

Treatment Decision Making in African American Women Diagnosed With Triple Negative Breast Cancer

Triple Negative Breast Neoplasms

NCT05730010 2023-08-03

Discerning the Impact of ctDNA Detection on Patient Decision Making in Early Stage Breast Cancer: a Conjoint Analysis

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05750719 2023-03-02

Light-Bright

Triple Negative Breast Neoplasms

NCT04368468 2022-12-23

MIMOSA

Triple Negative Breast Neoplasms

NCT03232593 2022-08-24

A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

BreastGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT00918892 2022-08-01

Assessment of Candidate Protein Expression in Breast Cancer Specimens

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01276899 2022-06-02

Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT02247037 2020-07-07

Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer

Triple Negative Breast Neoplasms

NCT03539965 2018-05-31

TNBCbrazil

Pathologic Complete Response, Triple Negative Breast Neoplasms

NCT01111175 2013-07-23

Triple Negative Breast Cancer Biomarker Study

Breast Neoplasms, Triple Negative Breast Neoplasms